Association of type 2 diabetes with cancer: A meta-analysis with bias analysis for unmeasured confounding in 151 cohorts comprising 32 million people
Figures are generally photos, graphs and static images that would be represented in traditional pdf publications.
Purpose: To assess how robust are the observational associations between (T2D) and cancer to unmeasured confounding.
Data sources: PubMed, Web of Science, and the Cochrane library were systematically searched on January 10th, 2019.
Study selection: Observational studies investigating associations between T2D and cancer incidence or mortality.
Data extraction: Cohort-level relative risk (RR).
Data Synthesis: RRs were combined in random-effects meta-analyses and pooled estimates used in bias analyses. A total of 151 cohorts (over 32 million people, 1.1 million cancer cases and 150,000 cancer deaths) were included. In meta-analyses, T2D was associated with incidence of several cancers, from prostate (RR 0.83; 95% CI: 0.79, 0.88) to liver (2.23; 1.99, 2.49); and mortality of pancreatic cancer (1.67; 1.30, 2.14). In bias analyses, assuming an unmeasured confounding associated with both T2D and cancer with a RR of 1.5, the proportion of studies with a true effect size larger than a RR of 1.1 (i.e., 10% increased risk in individuals with T2D) was nearly 100% for liver, pancreatic, and endometrial; 86% for gallbladder; 67% for kidney; 64% for colon; 62% for colorectal; and less than 50% for other cancer incidence, and 92% for pancreatic cancer mortality.
Limitations: Biases other than unmeasured confounding were not analytically assessed.
Conclusions: Our findings strongly suggest a causal association between T2D and liver, pancreatic, and endometrial cancer incidence, and pancreatic cancer mortality; conversely, associations with other cancers were less robust to unmeasured confounding.